Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Notes Payables (2019 - 2025)

Biodesix (BDSX) has disclosed Notes Payables for 7 consecutive years, with $6000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Notes Payables fell 71.43% year-over-year to $6000.0, compared with a TTM value of $6000.0 through Dec 2025, down 71.43%, and an annual FY2025 reading of $6000.0, down 71.43% over the prior year.
  • Notes Payables was $6000.0 for Q4 2025 at Biodesix, down from $11000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $14.3 million in Q3 2022 and bottomed at $6000.0 in Q4 2025.
  • Average Notes Payables over 5 years is $1.6 million, with a median of $47000.0 recorded in 2022.
  • The sharpest move saw Notes Payables crashed 99.92% in 2021, then skyrocketed 71570.0% in 2022.
  • Year by year, Notes Payables stood at $19000.0 in 2021, then soared by 157.89% to $49000.0 in 2022, then grew by 4.08% to $51000.0 in 2023, then crashed by 58.82% to $21000.0 in 2024, then tumbled by 71.43% to $6000.0 in 2025.
  • Business Quant data shows Notes Payables for BDSX at $6000.0 in Q4 2025, $11000.0 in Q3 2025, and $16000.0 in Q2 2025.